Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Reexamination Certificate
2005-05-02
2009-11-03
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
C424S489000, C424S499000, C530S390500
Reexamination Certificate
active
07611709
ABSTRACT:
Disclosed are applications of oligosaccharides/oligosaccharide mixtures for the production and stabilization of pharmaceutical compositions, chiefly powders, that contain antibodies or antibody derivatives as pharmaceutical active substance. The production of powders is accomplished through spray drying or freeze drying. Also disclosed are the corresponding antibody-containing powders as well as processes for their production.
REFERENCES:
patent: 3634582 (1972-01-01), Hartley et al.
patent: 3894146 (1975-07-01), Tsuyama
patent: 3906950 (1975-09-01), Cocozza
patent: 4013075 (1977-03-01), Cocozza
patent: 4570630 (1986-02-01), Elliott et al.
patent: 4811731 (1989-03-01), Newell et al.
patent: 5035237 (1991-07-01), Newall et al.
patent: 5296473 (1994-03-01), Hara et al.
patent: 5320094 (1994-06-01), Laube et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5489577 (1996-02-01), Ikeda et al.
patent: 5505945 (1996-04-01), Gristina et al.
patent: 5522385 (1996-06-01), Lloyd et al.
patent: 5626874 (1997-05-01), Conte et al.
patent: 5672581 (1997-09-01), Rubsamen et al.
patent: 5753469 (1998-05-01), Nakada et al.
patent: 5785049 (1998-07-01), Smith et al.
patent: 5922324 (1999-07-01), Aga et al.
patent: 5947118 (1999-09-01), Hochrainer et al.
patent: 5972388 (1999-10-01), Sakon et al.
patent: 6453795 (2002-09-01), Eicher et al.
patent: 2003/0059511 (2003-03-01), Ishii
patent: 2005/0191246 (2005-09-01), Bechtold-Peters et al.
patent: 2005/0250704 (2005-11-01), Bassarab et al.
patent: 2005/0250705 (2005-11-01), Bassarab et al.
patent: 2005/0255119 (2005-11-01), Bassarab et al.
patent: 2006/0008574 (2006-01-01), Begli et al.
patent: 2007/0298116 (2007-12-01), Bechtold-Peters et al.
patent: 2008/0089849 (2008-04-01), Schultz-Fademrecht et al.
patent: 2273241 (1998-07-01), None
patent: 2273277 (1998-07-01), None
patent: 2297174 (1999-02-01), None
patent: 2565019 (2005-12-01), None
patent: 19732351 (1999-02-01), None
patent: 19953727 (2001-05-01), None
patent: 129985 (1985-01-01), None
patent: 237507 (1987-09-01), None
patent: 467172 (1992-01-01), None
patent: 0630651 (1994-12-01), None
patent: 00630651 (1994-12-01), None
patent: 0739986 (1996-10-01), None
patent: 0745382 (1996-12-01), None
patent: 0911037 (1999-04-01), None
patent: 0974358 (2000-01-01), None
patent: 1174148 (2002-01-01), None
patent: 1223175 (2002-07-01), None
patent: 89/11297 (1989-11-01), None
patent: 90/13328 (1990-11-01), None
patent: 91/14468 (1991-10-01), None
patent: 94/07607 (1994-04-01), None
patent: 94/28958 (1994-12-01), None
patent: 95/31479 (1995-11-01), None
patent: 96/09814 (1996-04-01), None
patent: 96/32096 (1996-10-01), None
patent: 96/32149 (1996-10-01), None
patent: 97/04801 (1997-02-01), None
patent: 97/12683 (1997-04-01), None
patent: 97/12687 (1997-04-01), None
patent: 97/20590 (1997-06-01), None
patent: 97/41031 (1997-11-01), None
patent: 97/41833 (1997-11-01), None
patent: 97/44013 (1997-11-01), None
patent: 98/16205 (1998-04-01), None
patent: 98/31346 (1998-07-01), None
patent: WO 9927071 (1999-06-01), None
patent: 99/66903 (1999-12-01), None
patent: WO 00/09164 (2000-02-01), None
patent: 00/10541 (2000-03-01), None
patent: 01/00263 (2001-01-01), None
patent: 01/13893 (2001-03-01), None
patent: 01/32144 (2001-10-01), None
patent: 02/43750 (2002-06-01), None
patent: WO 03041512 (2003-05-01), None
patent: WO 03/064473 (2003-08-01), None
patent: WO 03080027 (2003-10-01), None
patent: 2005/112996 (2005-12-01), None
patent: 2005112892 (2005-12-01), None
patent: 2008055951 (2008-05-01), None
G. Xie, et al., “The thermodynamic mechanism of protein stabilization by trehalose”. Biophysical Chemistry, vol. 64, No. 1, 1997, pp. 25-43.
G. Xie, et al., “Mechanism of the stabilization of ribonuclease A by sorbitol: Preferential hydration is greater for the denatured than for the native protein”. Protein Science, vol. 6, 1997, pp. 211-221.
S. N. Timasheff. “The control of protein stability and association by weak interactions with water: How do solvents affect these processes?”. Annual Rev. Biophysics and Biomolecular Structure, vol. 22, 1993, pp. 67-97.
A. M. Boctor, et al., “Enhancement of the stability of thrombin by polyols: microcalorimetric studies”. Journal of Pharmacy and Pharmacology, vol. 44, No. 7, 1992, pp. 600-603.
B. S. Chang, et al., “Stabilization of lyophilized porcine pancreatic elastase”. Pharmaceutical Research, vol. 10, No. 10, 1993, pp. 1478-1483.
A. C. Herman, et al., “Characterization, formulation, and stability of neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factors”. Pharmaceutical Biotechnology, vol. 9, 1996, pp. 303-328.
H.K. Chan, et al., “Effects of additives on heat denaturation of rhDNase in solutions”. Pharmaceutical Research, vol. 13, No. 5, 1996, pp. 756-761.
J. Zhang, et al., “NMR study of the cold, heat, and pressure unfolding of ribonuclease A”. Biochemistry, 1995, vol. 34, No. 27, pp. 8631-8641.
R. L. Remmele, Jr., et al., “Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry”. Pharmaceutical Research, vol. 15, No. 2, 1998, pp. 200-208.
Y. F. Maa, et al., “Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders”. Pharmaceutical Research, Vol. 15, No. 5, 1998, pp. 768-775.
J. Broadhead, et al., “The effect of process and formulation variables on the properties of spray-dried b-galactosidase”. Journal Pharm. Pharmacol, 1994, vol. 46, No. 6, pp. 458-467.
M. T. Vidgren, et al., “Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate”. Int. J. Pharmaceutics, vol. 35, 1987, pp. 139-144.
R. W. Niven, et al., “Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit”. Pharmaceutical Research, vol. 11, No. 8, 1994, pp. 1101-1109.
Y. F. Maa, et al., “The effect of operating and formulation variables on the morphology of spray-dried protein particles”. Pharmaceutical Development and Technology, vol. 2, No. 3, 1997, pp. 213-223.
H. R. Costantino, et al., “Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody”. Journal of Pharmaceutical Sciences, Vo.87, No. 11, 1998, pp. 1406-1411.
C. Bosquillon, et al., “Influence of formation excipients and physical characteristics of inhalation dry powders on their aerosolization performance”. Journal of Controlled Release, vol. 70, No. 3, 2001, pp. 329-339.
J. S. Huston, et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia Coli”. Proc. Natl. Acad. Sci., USA, vol. 85, 1988, pp. 5879 ff.
O. Perisic, et al., “Crystal structure of a diabody, a bivalent antibody fragment”. Structure, vol. 2, 1994, pp. 1217 ff.
S. Z. Hu., et al., “Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts”. Cancer Research, vol. 56, 1996, pp. 3055 ff.
B. Lovejoy, et al. “Crystal structure of a synthetic triple-standard a-Helical bundle”. Science, vol. 259, 1993, pp. 1288 ff.
P. Pack, et al., “Tetravalent miniantibodies with high avidity assembling inEscherichia coli”. Journal Mo. Biol., 1995, 1995, 246, p. 28-34.
P. Pack, et al., “Improved bivalent miniantibodies, with identical avidy as whole antibodies, produced by high cell density fermentation ofEscherichia coli”. Bio/technology, vol. 11, 1993, pp. 1271 ff.
M. Adler, et al., “Stability and surface activity of lactate dehydrogenase in spray-dried trehalone”. Journal of Pharmaceutical
Bassarab Stefan
Bechtold-Peters Karoline
Friess Wolfgang
Fuhrherr Richard
Garidel Patrick
Boehringer Ingelheim Pharma GmbH and Co. KG
Bottino Anthony P.
Devlin Mary-Ellen M.
Morris Michael P.
Saunders David A
LandOfFree
1,4 O-linked saccharose derivatives for stabilization of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4 O-linked saccharose derivatives for stabilization of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4 O-linked saccharose derivatives for stabilization of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110381